Before a video consultation, an overseas retina specialist should have reviewed your eye scans, treatment history and diabetes records. The call is not simply a chance to describe an experimental procedure. It is where the specialist checks what is causing your vision loss, whether established care has been fully considered and whether a particular research protocol could be appropriate.
Stem cell therapy for diabetic retinopathy abroad remains investigational in most settings. It is not a proven cure or a routine substitute for injections, laser treatment, surgery, diabetes care or regular retinal examinations. A thoughtful consultation may end with advice not to proceed.
Before the call: what the retinal team needs to see
Send records before discussing eligibility or paying a deposit. A remote review can identify obvious concerns and worthwhile questions, but it cannot replace an examination at the destination. Your vision, eye pressure and retinal findings may need to be checked again in person before any procedure is approved.
Have these diabetic retinopathy records ready
- ✓ Eye findings: recent retinal examination notes, visual-acuity results, eye-pressure readings and reports from both eyes.
- ✓ Images: optical coherence tomography scans, retinal photographs and fluorescein angiography if performed. Ask whether the team needs the original image files, not just written reports.
- ✓ Past care: dates and responses to anti-VEGF injections, steroid treatment, laser procedures or vitrectomy, including any complications.
- ✓ General health: type of diabetes, recent glucose-control results, blood pressure, kidney and heart history, smoking status, medication list and allergies.
- ✓ Local support: contact details for the retina specialist and diabetes clinician who could continue care after you return.
Ask back: “Which records are missing, and what can you decide from them before I travel?”
A clear answer sounds like: “Your scans support a preliminary review, but eligibility and the treatment plan depend on an in-person retinal examination and the protocol’s screening tests.”
First, the specialist explains what your scans actually show
Diabetic retinopathy develops when diabetes damages the retina, the light-sensing tissue at the back of the eye. The specialist should grade each eye separately. Non-proliferative diabetic retinopathy (NPDR) ranges from mild to severe vessel damage without the abnormal new vessels that define proliferative diabetic retinopathy (PDR). PDR can cause bleeding and traction, where scar tissue pulls on the retina.
You may also have diabetic macular edema (DME), fluid swelling in the central retina that affects reading and detailed vision. Other findings include retinal ischemia, meaning inadequate blood supply, and possible retinal neurodegeneration, or damage to retinal nerve cells. These problems can occur with type 1 or type 2 diabetes. Vision impairment may reflect swelling, bleeding, ischemia, nerve damage or more than one cause.
If you have been told your disease is “refractory,” ask what that means in your case. It should describe an inadequate response to documented, appropriately delivered established treatment, not merely persistent symptoms after one visit. The specialist should also check for other eye conditions that stem cells would not address.
These terms help you follow the discussion and read a proposed treatment plan:
OCT: optical coherence tomography, a scan showing retinal layers and macular swelling.
Fluorescein angiography: imaging with an injected dye to show leaking vessels and areas with poor blood flow.
Neovascularization: fragile, abnormal new blood vessels associated with PDR.
Visual acuity: how clearly you see on a standardized vision chart, which may differ from how well you manage daily tasks.
Ask back: “Which finding is responsible for most of my vision loss, and how is each eye graded?”
A clear answer sounds like: “Your scan shows central swelling in one eye, while the other has advanced ischemia. Those findings have different established treatment options and different prospects for improvement.”
Next, the specialist checks whether a research protocol fits you
Being interested in stem cells does not establish eligibility. A legitimate study or investigational program has written entry and exclusion criteria. The specialist should match those criteria to the grade of your retinopathy, your vision, previous treatments and the stability of your eyes. Active bleeding, retinal detachment, infection or another urgent problem may require established care first.
Your general health matters too. The team may review glucose control, blood pressure, kidney disease, cardiovascular risk and medicines that affect bleeding or immunity. Older age or diabetes itself does not automatically rule you out. Smoking and a high body mass index may affect healing, anesthesia planning or study eligibility, depending on the protocol. The clinician should explain any exclusion rather than applying a blanket rule.
Ask who will make the final decision: a retina specialist, a study investigator, or both. If a surgical procedure is proposed, establish who will operate and who is available to treat an eye complication. Preliminary acceptance from emailed scans is not final medical clearance.
Ask back: “Which eligibility criteria do I meet, which are uncertain, and what could rule me out after arrival?”
A clear answer sounds like: “We can assess your records provisionally. We still need to repeat imaging, examine both eyes and review your health tests before deciding whether you qualify.”
Then, you should hear what could help without stem cells
A responsible consultation compares an investigational offer with treatment available to you at home. Improving diabetes and blood-pressure management, stopping smoking where relevant and attending retinal monitoring help protect vision, although they may not reverse existing damage. For DME or active PDR, a retina specialist may recommend anti-VEGF injections, which block a signal that encourages leaky abnormal vessels.
Other established options may include corticosteroid treatment for selected DME cases, retinal laser treatment for particular patterns of disease and vitrectomy to remove persistent bleeding or address traction-related problems. The best choice depends on the eye findings and what you have already tried. Even if you join a cell-therapy study, ask which standard treatments can continue and whether the protocol restricts them.
Treatment at home may offer easier repeat injections, monitoring and emergency access. Overseas research may offer access to a specific protocol, but adds travel demands and divides follow-up between teams. Neither location is automatically the better clinical choice.
Ask back: “Which established treatment would you recommend if I did not enter this program, and what would I give up by participating?”
A clear answer sounds like: “Your macular swelling still has an established treatment option. The research protocol has uncertain benefit and would require us to coordinate any additional injections with your local specialist.”
Only then should the specialist describe the proposed cell procedure
“Stem cell therapy” is not one standardized operation. Research approaches differ in cell type, source, processing, delivery method and intended effect. Some investigate whether cells might influence inflammation or tissue repair. Those ideas do not establish that the treatment restores damaged retinal blood supply or lost sight.
Possible approaches include cells derived from your own tissue or a donor, laboratory-expanded cells, or cells produced from other stem-cell lines. Delivery might involve an injection into the vitreous gel inside the eye, a procedure near or under the retina, or another route specified by the protocol. These approaches have different risks and should not be treated as interchangeable.
The specialist should be able to walk you through the exact protocol in this order:
- Confirm eligibility. Repeat retinal imaging, vision testing and any required general health tests in person.
- Review consent and product details. Explain the research aim, cell source, laboratory processing, quality checks, regulatory authorization and alternatives.
- Prepare the eye and deliver the cells. Describe the delivery route, anesthesia, infection-prevention steps, treating clinician and whether an operating facility is needed.
- Check the eye afterward. Monitor vision, eye pressure, inflammation and the retina, with a plan for urgent assessment if symptoms develop.
Request the cell product’s exact name or identifier, source, processing facility and release-testing information in writing. If the clinic names a proprietary product or brand, confirm what it contains and whether that precise product is authorized for your proposed use. Product names and regulatory status can differ between jurisdictions. A general statement that cells are “approved” is not enough.
Ask back: “What exactly enters my eye, how is it delivered, and where can I read the study protocol or authorization?”
A clear answer sounds like: “Here is the product identifier, its source, the planned delivery route, the registered protocol and the approval for this investigation. We will explain who performs each step.”
The safety discussion should cover both eye risks and research uncertainty
Potential harms depend on the product and delivery technique. They may include eye infection, inflammation, raised eye pressure, bleeding, retinal tears or detachment, abnormal tissue growth, immune reactions and further loss of vision. Collecting your own cells or receiving anesthesia can introduce additional risks. Some serious harms may emerge later, which is why long-term monitoring matters.
Be wary of a universal complication percentage. Cell products and delivery methods vary, and there is no reliable single risk range or success rate for stem cell treatment of diabetic retinopathy. Ask for protocol-specific results, including how many people were treated, what happened to them and how long they were followed.
The team should explain how it would detect and manage each major complication. An eye infection may require urgent examination and treatment. A retinal detachment may require surgery. Because you live elsewhere, establish which problems the overseas team can assess by reviewing scans remotely and which require immediate care from a local eye emergency service.
Ask back: “Who examines me urgently if vision worsens after I go home, and who pays for care or another trip if a complication needs treatment?”
A clear answer sounds like: “Seek urgent local eye care for sudden symptoms. We will provide your records and speak with that specialist, but a complication requiring an examination or procedure cannot be managed by video alone. These are the written terms for additional care.”
Expected results must be tied to a measurable goal
Ask what the protocol is testing. A study might measure safety, changes on OCT, retinal vessel findings, visual-acuity scores or quality of life. A scan that looks different does not necessarily mean you will read better or see more clearly. Existing retinal damage may limit improvement even when swelling decreases.
There is no established success range or reliable duration of benefit for this investigational treatment. If a provider quotes a percentage, ask for the source, number of participants, definition of “success,” comparison group and length of follow-up. Clarify whether further treatment may be necessary and whether you can receive established care if the procedure does not help.
Ask back: “What change would count as a meaningful result for my eye, and what evidence supports that expectation?”
A clear answer sounds like: “The main goal is to assess safety. A vision benefit is uncertain, and we will compare your examination and scans with your baseline at scheduled reviews.”
Before booking travel, test the offer against the written plan
Ask for the investigator’s retina qualifications, the facility’s license to perform the proposed eye procedure, the cell-processing laboratory’s quality standards and the research oversight that applies. If the proposal describes a trial, obtain its registry identifier and confirm that the actual product, condition, investigator and location match. Ask who provides emergency retinal surgery if needed.
Comparing destinations should focus on whether the specific protocol is authorized, whether the facility can manage its complications and whether follow-up can be coordinated with your doctor. Compare overseas plans on diagnosis, eligibility rules, cell source, delivery route, treating clinician, safety monitoring, expected outcome measures, local-care arrangements and total quoted cost. The cheapest plan is not necessarily the safest or best match.
There is no dependable international price range for this heterogeneous experimental treatment. Costs may change with cell processing, diagnostics, procedure complexity, anesthesia, facility use, repeat visits and complication care. Ask whether a legitimate study covers any research-related costs and what, if anything, you would pay. Distinguish the treatment quote from travel and living expenses.
Get inclusions and exclusions in writing. Check consultations, screening tests, laboratory work, clinician and facility fees, anesthesia, medicines, imaging, follow-up, emergency treatment, accommodation and transfers. A credible proposal names the provider and product, gives a clinical rationale, explains risks and uncertainty, sets out the treatment and review plan, and states the full payment terms. Vague guarantees of restored vision or unexplained charges need clarification.
Most medical preparation happens at home. Work with your own clinicians on diabetes and blood-pressure care, arrange any requested tests and review medicines with the treating team. Do not stop prescribed medicines on your own. Confirm that your local retina specialist can receive updates and see you promptly if a problem arises.
Plan to arrive early enough for the required in-person assessment, and remain near the treating team through the initial safety checks. The appropriate travel schedule depends on the delivery route, your examination and whether complications occur. A companion may help if vision is limited or you cannot travel independently after the procedure. A PlacidWay patient coordinator can help you obtain destination, price and individualized travel details.
Ask back: “What must be completed before I pay, what might change after screening, and what is excluded from the quote?”
A clear answer sounds like: “Here are the protocol, screening requirements, named treating team, proposed timeline and itemized terms. You are not guaranteed treatment until the in-person assessment is complete.”
Finally, map recovery and long-term care across both countries
Recovery differs substantially between an injection-based protocol and a retinal operation. The specialist should give you a procedure-specific plan rather than a universal promise about when you can fly or resume activities. Ask which checks must occur near the treating team and what findings must be stable before departure.
Immediately after treatment, near the clinic → The team checks for early discomfort, pressure changes, bleeding or inflammation and explains any activity restrictions.
Before departure, near the clinic → Repeat examination or imaging confirms whether travel is appropriate and whether you need further local observation.
After returning home → Your local retina specialist performs scheduled vision tests and scans, while the overseas investigator reviews results required by the protocol.
Long term → Continue diabetes care and retinal monitoring. You may still need injections, laser treatment or surgery for diabetic retinopathy.
Know the warning signs: sudden vision loss, new flashes or a curtain across your vision, increasing floaters, marked pain, worsening redness or light sensitivity need urgent local eye assessment. Contacting the overseas clinic is useful, but it must not delay emergency care.
Before leaving, collect your discharge summary, procedure report, cell product identifier and batch information where applicable, examination findings, imaging, prescriptions, restrictions, emergency contacts and a written follow-up schedule. Give copies to your local retina specialist. The two teams should agree who orders scans, who interprets them and how results are shared.
Ask about longer-term safety reviews, particularly for inflammation or abnormal tissue changes. If your retinopathy progresses, your local specialist will usually assess and treat the immediate problem. If a protocol-related revision or additional procedure is proposed overseas, clarify its clinical justification, who performs it and whether another trip would be required. Never assume repeat cell treatment is routine maintenance.
Ask back: “What must be checked before I leave, and who is responsible for each follow-up test once I am home?”
A clear answer sounds like: “We will give you the procedure details and scheduled tests in writing, review scans sent by your local specialist and tell you which symptoms require immediate local care.”
Discuss your diabetic retinopathy consultation options
If you are comparing investigational care abroad, speak with a PlacidWay patient coordinator about the records a provider needs and the questions to put to its retinal team.
References
- National Eye Institute — Diabetic Retinopathy
- U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products, Including Stem Cells and Exosomes
- ClinicalTrials.gov — Clinical Study Registry
- International Society for Stem Cell Research — A Closer Look at Stem Cells: Information for Patients
- American Diabetes Association — Eye Complications
This page is for general information and is not medical advice. Consult a qualified retina specialist and your diabetes clinician about your own diagnosis, treatment options and fitness for travel.
Who stands behind this article
Health content should never be anonymous. Here are the people who wrote and checked it, with credentials you can verify independently.
Usama
As the Editor of Global Stem Cell Therapy, I provide trusted, research-based information on stem cell treatments worldwide. With over a decade of experience in medical tourism, I guide patients toward safe, effective, and affordable therapies.
This author specializes in global healthcare trends and medical education. By focusing on evidence-based practices and a patient-first approach, they provide accessible resources to help readers understand their international treatment options with clarity.
Stem Cell Therapy, Longevity & Regenerative Medicine Specialist
Dr. Alejandro Fernando is a Mexico City-based physician and medical content reviewer focused on stem cell therapy, regenerative medicine, cellular therapy and longevity medicine. His reviewer profile lists medical and postgraduate training related to regenerative medicine, cellular therapy and stem cell biology.
How this article was checked
